

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”).

Reference is made to the prospectus of Legend Biotech Corporation (“**Legend**”), a subsidiary of the Company, filed with the United States Securities and Exchange Commission on 8 June 2020 (the “**Prospectus**”) in respect of the estimated timetable of obtaining the regulatory approval of CARTITUDE-1.

On 16 July 2020, Janssen Biotech, Inc., one of the Janssen Pharmaceuticals Companies of Johnson & Johnson, a strategic partner of Legend for the development of JNJ-4528 for the treatment of multiple myeloma, provided an update to the expected timing for the regulatory submissions for JNJ-4528 for the treatment of relapsed and/or refractory multiple myeloma (“**RRMM**”). Specifically, Janssen remains on track to initiate a biologics license application to the U.S. Food and Drug Administration (“**FDA**”) by the end of 2020 and also expects that a marketing authorization application will be submitted to the European Medicines Agency (“**EMA**”) in early 2021.

About CARTITUDE-1

LCAR-B38M and JNJ-68284528 (JNJ-4528) are investigational B-cell maturation antigen chimeric antigen receptor T-cell therapy being studied in RRMM. In the U.S., JNJ-4528 is currently being investigated in the phase 1b/2 CARTITUDE-1 (MMY2001, NCT03548207) registration study for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or are double refractory to a proteinase inhibitor (“**PI**”) and immunomodulatory drug (“**IMiD**”), received a PI, an IMiD, and anti-CD38 antibody and documented disease progression within 12 months of starting the most recent therapy.

Cautionary Statement

Certain information regarding the Company contained in this announcement may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what the Company currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include research and development results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained in this announcement is stated as of the current date and subject to change after that date.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 16 July 2020

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*